Metastatic Castration Resistant Prostate Cancer (MCRPC)

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

July 30th, 2024 | Metastatic Castration Resistant Prostate Cancer (MCRPC)

NCT Number: NCT04071236 Phase: PHASE1|PHASE2 Trial Summary: This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with c – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Complement Theory Inc. Acronym:

Pin It on Pinterest